Mattia D’Agostino - Concepedia

Author

Mattia D’Agostino

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino ORCID

Also Known As

Carlos Fernández de Larrea, D'Agostino Mattia, Daniel C. Rohrer, M D'Agostino, M. D'Agostino, M. D’Agostino, Maria Valeria D’Agostino, Mattia D'Agostino, Mattia D’Agostino, Mattia D’agostino

136

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino University of Turin Erasmus MC Cancer Institute University of Milan Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

About

Mattia D’Agostino is an author at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	144
2	Immunology	4	4	129
3	Pathology	4	4	92
4	Health Sciences	1	1	33
5	Cell Biology	1	1	52

Mattia D’Agostino

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project Mattia D’Agostino, David A. Cairns, Juan José Lahuerta, Journal of Clinical Oncology	2022	371
Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory Giacomo Oliveira, Eliana Ruggiero, Maria Teresa Lupo Stanghellini, Science Translational Medicine	2015	111
Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients Francesca Gay, Wilfried Roeloffzen, Meletios Α. Dimopoulos, Blood	2023	96
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma Hervé Avet‐Loiseau, Faith E. Davies, Mehmet Samur, Journal of Clinical Oncology	2025	76
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma Alessandra Larocca, Francesca Bonello, Gianluca Gaïdano, Blood	2021	75
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing Mattia D’Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, Clinical Cancer Research	2020	62
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension Sara Bringhen, Alberto Milan, Mattia D’Agostino, Journal of Internal Medicine	2019	58
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, Haematologica Relapsed/refractory PatientsImmunologyT CellsImmunotherapyTumor Biology	2021	52
Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial Francesca Gay, Pellegrino Musto, Delia Rota Scalabrini, Blood	2020	44
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial Stefania Oliva, Davine Hofste op Bruinink, Lucie Říhová, Blood Cancer Journal	2021	44

Page 1